Last €1.01 EUR
Change Today 0.00 / 0.00%
Volume 0.0
VSC On Other Exchanges
Symbol
Exchange
Xetra
OTC US
As of 2:10 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

4sc ag (VSC) Snapshot

Open
€0.99
Previous Close
€1.01
Day High
€1.03
Day Low
€0.99
52 Week High
09/13/13 - €2.05
52 Week Low
06/27/14 - €0.88
Market Cap
51.3M
Average Volume 10 Days
114.2K
EPS TTM
€-0.20
Shares Outstanding
50.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 4SC AG (VSC)

Related News

No related news articles were found.

4sc ag (VSC) Related Businessweek News

No Related Businessweek News Found

4sc ag (VSC) Details

4SC AG engages in the research and development of orally administered small-molecule drugs for autoimmune diseases and cancer. Its product pipeline in the area of autoimmune disease includes Vidofludimus 4SC-101, an oral autoimmune modulator of the DHODH enzyme and the IL-17 cytokine, which is in Phase II clinical trials for the treatment of inflammatory bowel diseases; and Vidofludimus 4SC-101, an oral autoimmune modulator of the DHODH enzyme and the IL-17 cytokine, which completed Phase II clinical trials for the treatment of rheumatoid arthritis. The company’s product pipeline in the area of oncology comprises Resminostat 4SC-201, an oral pan histone deacetylase (HDAC) inhibitor for the treatment of hepatocellular carcinoma, Hodgkin’s lymphoma, and colorectal cancer; 4SC-202, an oral selective HDAC inhibitor that completed Phase I for the treatment of hematologic tumors; 4SC-203, an oral multi-kinase inhibitor selective of FLT3 and VEGF, which completed Phase I studies for oncology; 4SC-205, an oral Eg5 kinesin spindle protein inhibitor that completed Phase I study for the treatment of solid tumors; and 4SC-207, an oral cell-cycle blocker that is under clinical studies for the treatment of solid tumors. It also conducts research programs in the areas of cancer stem cells, ion channel blockers, and cytokine modulation for the treatment of oncology and autoimmune diseases. The company was founded in 1997 and is headquartered in Martinsried, Germany.

Founded in 1997

4sc ag (VSC) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €278.0K
Co-Founder, Chief Scientific Officer, Chief D...
Total Annual Compensation: €198.0K
Compensation as of Fiscal Year 2013.

4sc ag (VSC) Key Developments

4SC AG Announces Positive Top Line Data from Clinical Phase I Trial with Epigenetic Cancer Drug 4SC-202 in Patients with Haematological Tumours at ACSO

4SC AG announced positive top line data from its clinical Phase I TOPAS study with 4SC's epigenetic cancer drug 4SC-202 in patients with advanced haematological tumours. 4SC-202, an oral small molecule inhibitor targeting WNT and Hedgehog (HH) signaling by specific inhibition of the epigenetic modifiers LSD1 and HDAC1, 2 and 3, was well tolerated, showed favorable pharmacokinetic properties and demonstrated promising signs of anti-tumour efficacy. The main study phase has been completed for all patients, with one complete responder patient still remaining on follow-up study treatment. The first-in-man, open-label, dose-escalating, multi-centre, exploratory study evaluated safety, pharmacokinetics and pharmacodynamics of 4SC-202 in 24, heavily pre-treated, patients with advanced stages of haematological malignancies. The compound was studied in doses from 25 mg up to 400 mg total daily dose of 4SC-202 using various dosing schemes. The drug showed promising signs of efficacy, both in terms of long-term disease stabilisation of heavily pre-treated cancer patients and in terms of tumour shrinkage and objective radiological response. There was one complete remission (CR) and one partial remission (PR). 50% of patients (12 out of 24) had disease stabilisation and time on study medication for more than 100 days, 13% were stabilised for over a year, and one patient could be stabilised for more than 2 years. The patient with the CR has been on the trial now for over 16 months, with both study treatment and CR still ongoing to date.

4SC AG Announces Consolidated Earnings Results for the First Quarter Ended 31 March 2014; Provides Earnings Guidance for 2014

4SC AG announced consolidated earnings results for the first quarter ended 31 March 2014. Consolidated revenue was EUR 1.44 million in the first quarter of 2014, almost double the figure in the comparative period in 2013 compared to EUR 0.79 million a year ago. This positive development was mainly attributable to the cooperation agreements with BioNTech AG and Leo Pharma A/S that began in 2013. The company's loss from operating activities decreased by 22% to EUR 2.12 million in the first quarter of 2014, primarily on the back of higher revenue compared to EUR 2.74 million a year ago. The net loss improved by 21% year on year to EUR 2.12 million or EUR 0.04 per share compared to loss of EUR 2.68 million or EUR 0.05 per share a year ago. This results in an average monthly outflow of cash from operations amounting to EUR 0.71 million in the reporting period compared to cash inflow from operations of EUR 0.06 million a year ago. The consolidated net loss for 2014 should improve further year-on-year due to cost reductions and the expected contributions by 4SC Discovery GmbH's positive activities to earnings. This estimate is based on the assumption that the average monthly operating cash burn rate in 2014 will be reduced to EUR 0.4 million and that the company's research and development programmes and existing partnerships will continue to run according to plan.

Yakult Honsha Co., Ltd. Completes Phase I Clinical Study with 4SC's Cancer Drug Resminostat

4SC AG announced that its Japanese partner Yakult Honsha Co. Ltd. has successfully completed a Japan-based Phase I clinical study with 4SC's cancer drug resminostat in patients with solid tumours. The study demonstrated the clean safety profile of resminostat in Japanese cancer patients, which is a key prerequisite of the resminostat's further clinical development in Japan. The successful completion of the study has also triggered a milestone payment from Yakult to 4SC. The open-arm, dose-escalating study evaluated safety and tolerability of resminostat in doses of up to 800 mg Resminostat in 12 Japanese patients with advanced solid tumours. In addition, the drug's pharmacokinetics and pharmacodynamics were investigated. Resminostat proved to be safe and well tolerated in all doses tested. The observed side effects were generally of moderate nature. These results confirm the clean safety profile which resminostat has already shown in several studies in Western patient populations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSC:GR €1.01 EUR 0.00

VSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSC.
View Industry Companies
 

Industry Analysis

VSC

Industry Average

Valuation VSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4SC AG, please visit www.4sc.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.